logo image

Lansoprazole information from DrugsUpdate  

See Available Brands of Lansoprazole in India

P - Caution when used during pregnancy
L - Caution when used during lactation

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol). It was first approved by the U.S. Food and Drug Administration (FDA) in 1995. Prevacid patent protection expired on November 10, 2009. As a result, prescription Lansoprazole is now available in the form of a generic drug.

Pharmacodynamics

Pharmacokinetics

Lansoprazole inhibits gastric acid secretion by inhibiting the H+/K+ ATPase, which is also known as the proton pump. Both basal and stimulated acid are inhibited.

Absorption

Rapidly absorbed from the GIT (oral); peak plasma concentrations after 1.5 hours.

Distribution
Protein-binding: 97%.

Metabolism
Extensively hepatic; converted to 5-hydroxyl-lansoprazole and lansoprazole sulfone.

Excretion
Via faeces (main) and urine (15-30% of a dose); 1-2 hours (elimination half-life).

Lansoprazole Indications / Lansoprazole Uses

Information Not Available

Lansoprazole Adverse Reactions / Lansoprazole Side Effects

Diarrhoea, abdominal pain, nausea, constipation, headache, dizziness, eosinophilia, myalgia, glossitis, stomatitis, rash.

Precautions

Symptomatic response to therapy with Lansoprazole does not preclude the presence of gastric malignancy.

Special Precautions

Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation.

Other Drug Interactions

Reduced bioavailability with antacids and sucralfate. May decrease the absorption of atazanavir, itraconazole and ketoconazole. May increase plasma concentration of cilostazol.

Other Interactions

Information Not Available

Dosage

Oral
Peptic ulcer
Adult: 30 mg once daily in the morning given for 4 weeks (duodenal ulcer) or for 8 weeks (gastric ulcer).

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Oral

Hypersecretory conditions
Adult: Initially, 60 mg daily and adjust as required. Daily doses >120 mg should be given in 2 divided doses.

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Oral
Acid-related dyspepsia
Adult: 15-30 mg once daily in the morning for 2-4 weeks.

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Oral
Gastro-oesophageal reflux disease
Adult: 30 mg once daily in the morning for 4-8 weeks. Maintenance: 15-30 mg once daily according to response.
Child: and erosive oesophagitis: 1-11 years: ≤30 kg: 15 mg once daily; >30 kg: 30 mg once daily. May increase doses up to 30 mg bid if patient is still symptomatic after 2 or more weeks of treatment. 12-17 years: For erosive oesophagitis: 30 mg once daily for up to 8 weeks; For nonerosive gastro-oesophageal reflux disease: 15 mg once daily for up to 8 weeks.

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Oral
NSAID-associated ulceration
Adult: 15-30 mg daily for 4-8 weeks.

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Oral
Prophylaxis of NSAID-induced ulcers
Adult: 15-30 mg daily for 4-8 weeks.

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Oral
H.pylori infection
Adult: 1-weeks triple therapy: 30 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid.

Hepatic impairment: Severe impairment: Max dose: 30 mg/day.

Intravenous
Erosive oesophagitis
Adult: 30 mg over 30 minutes daily for up to 7 days.

Hepatic impairment: Consider dose adjustment.

Food(before/after)

Should be taken on an empty stomach. (Take before meals.)

List of Contraindications

Lansoprazole and Pregnancy

Caution when used during pregnancy

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).

Lansoprazole and Lactation

Caution when used during lactation

Lansoprazole and Children

Safety and efficacy not established in children younger than 1 years of age. Safety and efficacy of lansoprazole IV has not been established in pediatric patients.

Lansoprazole and Geriatic

Information Not Available

Lansoprazole and Other Contraindications

Information Not Available

Storage

Intravenous
Store at 25°C (77°F).

Oral

Store at 25°C (77°F).

Lab interference

Intravenous
Store at 25°C (77°F).

Oral

Store at 25°C (77°F).

© 2011-2018 DrugsUpdate.com. Disclaimer | Site Map

Feedback